Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
John P. Neoptolemos(University of Liverpool), for the European Study Group for Pancreatic Cancer, Helmut Friess(Technical University of Munich), David Goldstein(New South Wales Department of Health), Charlotte Rawcliffe(University of Liverpool), Paula Ghaneh(University of Liverpool), Deborah Stocken(Cancer Research UK Clinical Trials Unit), Daniel H. Palmer(University of Liverpool), Markus W. Büchler(Heidelberg University), Attila Oláh(Semmelweis University), Jakob R. Izbicki(Universität Hamburg), Steven Gallinger(Mount Sinai Hospital), David Cunningham(Royal Marsden NHS Foundation Trust), Moritz N. Wente(Heidelberg University), Claudio Bassi(University of Verona), Juan W. Valle(Cancer Research UK Manchester Institute), Ryuichiro Doi(Kyoto University), Giovanni Butturini(University of Verona), Markus M. Lerch(Ludwig-Maximilians-Universität München), Pehr Lind(Karolinska Institutet), Christos Dervenis(Agia Olga Hospital), David B. Smith(Wirral University Teaching Hospital NHS Foundation Trust), John Buckels(University Hospitals Birmingham NHS Foundation Trust), Colin J. McKay(Glasgow Royal Infirmary), Joyce Thompson(University Hospitals Birmingham NHS Foundation Trust), C. Mariette(Hôpital Claude Huriez), Robert Padbury(Flinders Medical Centre), Malcolm J. Moore(University Health Network)
Cited by 1,388
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k